MA41299A - Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite - Google Patents

Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite

Info

Publication number
MA41299A
MA41299A MA041299A MA41299A MA41299A MA 41299 A MA41299 A MA 41299A MA 041299 A MA041299 A MA 041299A MA 41299 A MA41299 A MA 41299A MA 41299 A MA41299 A MA 41299A
Authority
MA
Morocco
Prior art keywords
conjunctivitis
glaucoma
treatment
ophthalmic solutions
ophthalmic
Prior art date
Application number
MA041299A
Other languages
English (en)
Inventor
George Anastassov
Lekhram Changoer
Original Assignee
Axim Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axim Biotechnologies Inc filed Critical Axim Biotechnologies Inc
Publication of MA41299A publication Critical patent/MA41299A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA041299A 2014-12-30 2015-12-28 Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite MA41299A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462098007P 2014-12-30 2014-12-30

Publications (1)

Publication Number Publication Date
MA41299A true MA41299A (fr) 2017-11-07

Family

ID=56162983

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041299A MA41299A (fr) 2014-12-30 2015-12-28 Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite

Country Status (4)

Country Link
US (2) US9814695B2 (fr)
EP (1) EP3240535A4 (fr)
MA (1) MA41299A (fr)
WO (1) WO2016109531A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101656121B1 (ko) 2010-03-17 2016-09-08 노바리크 게엠베하 안압 증가를 치료하기 위한 약학 조성물
CN113679697A (zh) 2012-09-12 2021-11-23 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
CA2883003C (fr) 2012-09-12 2021-11-16 Novaliq Gmbh Compositions d'alcanes semifluores
DK3722274T3 (da) 2015-09-30 2023-09-11 Novaliq Gmbh 2-perfluorbutylpentan til oftalmisk indgivelse
DE202016008738U1 (de) 2015-09-30 2019-04-09 Novaliq Gmbh Semifluorierte Verbindungen und ihre Zusammensetzungen
US10813976B2 (en) 2016-09-23 2020-10-27 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
AU2017333420A1 (en) * 2016-09-28 2019-04-04 Novaliq Gmbh Compositions comprising a cannabinoid receptor binding ligand
WO2018193093A1 (fr) 2017-04-21 2018-10-25 Novaliq Gmbh Compositions d'iode
EP3621656B1 (fr) * 2017-05-08 2023-11-29 Inmed Pharmaceuticals Inc. Formulation pour l'administration d'un médicament pour les yeux
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
CA3076776A1 (fr) 2017-09-27 2019-04-04 Novaliq Gmbh Compositions ophtalmiques comprenant du latanoprost, destinees a etre utilisees dans le traitement de maladies oculaires
CN120022260A (zh) 2017-10-04 2025-05-23 诺瓦利克有限责任公司 包含f6h8的眼用组合物
WO2019191800A1 (fr) * 2018-04-04 2019-10-10 Eye Co Pty Ltd Extrait de chanvre contenant une faible quantité de thc et méthode de traitement ou de prévention d'une maladie oculaire
EP3784246A1 (fr) 2018-04-27 2021-03-03 Novaliq GmbH Compositions ophtalmiques comprenant du tafluprost pour le traitement du glaucome
US11077150B2 (en) * 2018-10-09 2021-08-03 Massoumeh Kharazmi Methods and compositions for treatment of eye conditions
AU2019358249B2 (en) 2018-10-12 2024-02-22 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
EP3923907B1 (fr) 2019-02-13 2024-09-25 Novaliq GmbH Compositions et procédés pour le traitement de la néovascularisation oculaire
KR20220080045A (ko) * 2019-04-24 2022-06-14 인메드 파마슈티컬스 인코포레이티드 신경보호를 위한 칸나비노이드의 사용을 위한 조성물 및 방법
KR20220058577A (ko) 2019-09-06 2022-05-09 노바리크 게엠베하 포도막염 치료를 위한 안과용 조성물
CN119384280A (zh) * 2022-06-16 2025-01-28 广州润尔眼科生物科技有限公司 一种药物组合物及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU766988B2 (en) * 1998-04-21 2003-10-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Cannabinoids as antioxidants and neuroprotectants
US20090131313A1 (en) * 2005-06-17 2009-05-21 Regenerx Biopharmaceuticals, Inc. Lkktet and/or lkktnt peptide compositions and methods for treating or preventing tissue deterioration, injury or damage
US7612101B2 (en) 2006-04-24 2009-11-03 Allergan, Inc. Abnormal cannabidiols as agents for lowering intraocular pressure
US8222292B2 (en) * 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
DE102007046086A1 (de) * 2007-09-26 2009-04-09 Heinz Prof. Dr. Letzel Pflanzenextrakt aus THC-armen Cannabis zur Behandlung von Erkrankungen
EP2424525A1 (fr) * 2009-04-28 2012-03-07 AllTranz Inc. Préparations de cannabidiol et promédicaments de cannabidiol, et méthodes d'utilisation associées

Also Published As

Publication number Publication date
EP3240535A4 (fr) 2018-08-08
WO2016109531A1 (fr) 2016-07-07
US20160184259A1 (en) 2016-06-30
EP3240535A1 (fr) 2017-11-08
US9844530B1 (en) 2017-12-19
US9814695B2 (en) 2017-11-14

Similar Documents

Publication Publication Date Title
MA41299A (fr) Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite
EP3347469A4 (fr) Méthodes et compositions pour le traitement du glaucome
EP3390634A4 (fr) Compositions et méthodes pour le traitement de maladies oculaires
EP3374502A4 (fr) Procédés pour le traitement de dystrophies cornéennes
MA49144A (fr) Polythérapies pour le traitement du cancer
EP3370703A4 (fr) Combinaison de gemcabène pour le traitement de maladies cardiovasculaires
MA39748A (fr) Cenicriviroc pour le traitement de la fibrose
EP3448875A4 (fr) Compositions pour le traitement de maladies
MA41028A (fr) Méthodes et formulations pour le traitement de pathologies oculaires vasculaires
EP3302379A4 (fr) Compositions et méthodes pour le traitement du ptérygion
ME03314B (fr) Thérapie basée sur l'arnm pour le traitement des maladies oculaires
EP3313325A4 (fr) Échafaudages implantables pour le traitement de la sinusite
EP3504187A4 (fr) Utilisation de la pridopidine pour le traitement du déclin fonctionnel
MA50409A (fr) Polythérapies pour le traitement du cancer
MA48637A (fr) Polythérapies pour le traitement du cancer
MA41449A (fr) Polythérapies pour le traitement de cancers
MA42999A (fr) Polythérapie pour le traitement de malignités
EP3389645A4 (fr) Combinaisons pour le traitement du cancer
EP3359255A4 (fr) Polythérapies pour le traitement du cancer
MA53568A (fr) Médicaments pour le traitement de maladies ophtalmiques
EP3335041A4 (fr) Biomarqueurs pour le traitement de la pelade
EP3334432A4 (fr) Cerdulatinib pour le traitement du myélome
EP3316887A4 (fr) Inhibiteurs de gls1 pour le traitement de maladies
EP3636252A4 (fr) Goutte ophtalmique pour le traitement de la sécheresse oculaire
MA39927A (fr) Inhibiteurs de glyt1 pour le traitement de troubles hématologiques